Hunt & Hess Classification of Subarachnoid Hemorrhage

Hunt & Hess Classification of Subarachnoid Hemorrhage

Assesses SAH severity and predict patient prognosis

Hunt & Hess Classification of Subarachnoid Hemorrhage

Hunt & Hess Classification of Subarachnoid Hemorrhage

Assesses SAH severity and predict patient prognosis

Clinical Presentation
Select the best matching symptoms for SAH severity
Hunt & Hess Grade —
Choose one option in the card

Instructions

The Hunt and Hess Classification is used to grade the severity of subarachnoid hemorrhage (SAH) based on the patient’s clinical presentation, particularly neurological status.

Overview
When to use
Why use
Evidences

Interpretation

Grade

Clinical Presentation

I

Asymptomatic or mild headache, slight nuchal rigidity

II

Moderate to severe headache, nuchal rigidity, no neurologic deficit except cranial nerve palsy

III

Drowsiness, confusion, or mild focal neurologic deficit

IV

Stupor, moderate-to-severe hemiparesis, early decerebrate rigidity, vegetative disturbances

V

Deep coma, decerebrate posturing, moribund appearance

 

The Hunt & Hess (H&H) classification grades aneurysmal subarachnoid hemorrhage (aSAH) from 1 to 5 based on clinical condition at presentation to estimate prognosis; it remains widely used alongside WFNS and imaging-based (Fisher/modified Fisher) scales, and contemporary guidelines still reference it for risk stratification and communication.
https://www.ncbi.nlm.nih.gov/books/NBK441958/

 

H&H has been used for decades to estimate operative risk and outcomes after aSAH, with mortality rising across grades and guiding triage to neurosurgical care; radiographic scales (Fisher/modified Fisher) complement H&H by predicting vasospasm risk based on CT blood burden
https://pmc.ncbi.nlm.nih.gov/articles/PMC3621041/

 

Prospective and retrospective cohorts show H&H, WFNS (GCS-based), and PAASH all have broadly similar discrimination for poor outcomes, with AUROC values around 0.83–0.84 for 90‑day poor outcome in one multicenter cohort, though individual adjacent-grade separations differ among scales.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10130082/

 

The 2023 AHA/ASA aSAH guideline endorses using established clinical grading scales (H&H or WFNS) with imaging scales (Fisher/modified Fisher) to stratify severity, communicate risk, and inform monitoring and intervention strategies; none alone dictates management decisions.
https://www.stroke-manual.com/wp-content/uploads/2024/03/2023-AHA-ASA-SAH-guidelines.pdf

Overview
When to use
Why use
Evidences

The Hunt and Hess Classification is a well-established clinical tool used in patients with aneurysmal subarachnoid hemorrhage (SAH) to estimate severity at presentation and guide prognosis. First introduced in 1968, it has remained widely used in neurology, neurosurgery, and critical care as a practical method to stratify risk.

The scale categorizes patients into five grades based on clinical symptoms such as headache, level of alertness, neurological deficits, and signs of increased intracranial pressure. Lower grades (I–II) generally indicate a better prognosis and lower operative risk, while higher grades (IV–V) suggest severe neurological compromise and poor outcomes.

The Hunt and Hess scale helps clinicians communicate the severity of SAH, make treatment decisions, and estimate survival probabilities. For instance, patients with lower grades may be candidates for early surgical or endovascular intervention, while those with higher grades often require stabilization and supportive management before definitive treatment.

 

Overview
When to use
Why use
Evidences

Interpretation

Grade

Clinical Presentation

I

Asymptomatic or mild headache, slight nuchal rigidity

II

Moderate to severe headache, nuchal rigidity, no neurologic deficit except cranial nerve palsy

III

Drowsiness, confusion, or mild focal neurologic deficit

IV

Stupor, moderate-to-severe hemiparesis, early decerebrate rigidity, vegetative disturbances

V

Deep coma, decerebrate posturing, moribund appearance

 

The Hunt & Hess (H&H) classification grades aneurysmal subarachnoid hemorrhage (aSAH) from 1 to 5 based on clinical condition at presentation to estimate prognosis; it remains widely used alongside WFNS and imaging-based (Fisher/modified Fisher) scales, and contemporary guidelines still reference it for risk stratification and communication.
https://www.ncbi.nlm.nih.gov/books/NBK441958/

 

H&H has been used for decades to estimate operative risk and outcomes after aSAH, with mortality rising across grades and guiding triage to neurosurgical care; radiographic scales (Fisher/modified Fisher) complement H&H by predicting vasospasm risk based on CT blood burden
https://pmc.ncbi.nlm.nih.gov/articles/PMC3621041/

 

Prospective and retrospective cohorts show H&H, WFNS (GCS-based), and PAASH all have broadly similar discrimination for poor outcomes, with AUROC values around 0.83–0.84 for 90‑day poor outcome in one multicenter cohort, though individual adjacent-grade separations differ among scales.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10130082/

 

The 2023 AHA/ASA aSAH guideline endorses using established clinical grading scales (H&H or WFNS) with imaging scales (Fisher/modified Fisher) to stratify severity, communicate risk, and inform monitoring and intervention strategies; none alone dictates management decisions.
https://www.stroke-manual.com/wp-content/uploads/2024/03/2023-AHA-ASA-SAH-guidelines.pdf

Frequently Asked Questions

Features and Services FAQs

Discover the full range of features and services we offer and how to use them.

What condition does the Hunt and Hess scale apply to?+
How is the grade determined?+
Can imaging findings alter the Hunt and Hess grade?+
How does it compare to the WFNS scale?+
Is it predictive of outcomes?+
Can a patient’s grade change over time?+

Ready to Transform Your Practice?

Join thousands of clinicians saving hours daily with AI-powered documentation.

14-day free trial • No setup fees

Ready to Transform Your Practice?

Join thousands of clinicians saving hours daily with AI-powered documentation.

14-day free trial • No setup fees

Ready to Transform Your Practice?

Join thousands of clinicians saving hours daily with AI-powered documentation.

14-day free trial • No setup fees

DocScrib

AI-powered medical documentation platform revolutionizing clinical workflows through intelligent patient management and secure documentation.

© 2025 DocScrib. All rights reserved.

DocScrib

AI-powered medical documentation platform revolutionizing clinical workflows through intelligent patient management and secure documentation.

© 2025 DocScrib. All rights reserved.

DocScrib

AI-powered medical documentation platform revolutionizing clinical workflows through intelligent patient management and secure documentation.

© 2025 DocScrib. All rights reserved.